A New Activity of N-Cholinolytic Drug Benzohexonium

We have found that N-cholinolytic drug benzohexonium produces a hypolipidemic effect: it reduces dyslipoproteinemia, fatty infiltration of the liver, and risk of atherosclerotic lesions.

Saved in:
Bibliographic Details
Published in:Bulletin of experimental biology and medicine 2012-08, Vol.153 (4), p.487-489
Main Authors: Khnychenko, L. K., Okunevich, I. V., Losev, N. A., Sapronov, N. S., Yakovleva, E. E.
Format: Article
Language:English
Subjects:
Analysis of Variance
Animals
Biomedical and Life Sciences
Biomedicine
Cell Biology
Cholinergic Antagonists - pharmacology
Cholinergic Antagonists - therapeutic use
Disease Models, Animal
Dyslipidemias - drug therapy
Fatty Liver - drug therapy
Guinea Pigs
Hexamethonium Compounds - pharmacology
Hexamethonium Compounds - therapeutic use
Hypertension
Hypolipidemic Agents - pharmacology
Hypolipidemic Agents - therapeutic use
Internal Medicine
Laboratory Medicine
Lipid Metabolism - drug effects
Male
Pathology
Plaque, Atherosclerotic - prevention & control
Rats
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We have found that N-cholinolytic drug benzohexonium produces a hypolipidemic effect: it reduces dyslipoproteinemia, fatty infiltration of the liver, and risk of atherosclerotic lesions.
ISSN:0007-4888
1573-8221
DOI:10.1007/s10517-012-1748-y